Source Themes

The rapidly evolving field of single-cell transcriptomics has provided a powerful means for understanding cellular heterogeneity. Large-scale studies with multiple biological samples hold promise for discovering differentially expressed biomarkers with a higher level of confidence through a better characterization of the target population. However, the hierarchical nature of these experiments introduces a significant challenge for downstream statistical analysis. Indeed, despite the availability of numerous differential expression methods, only a select few can accurately address the within-patient correlation of single-cell expression profiles. Furthermore, due to the high computational costs associated with some of these methods, their practical use is limited. In this manuscript, we undertake a comprehensive assessment of different strategies to address the hierarchical correlation structure in multi-sample scRNA-seq data. We employ synthetic data generated from a simulator that retains the original correlation structure of multi-patient data while making minimal assumptions, providing a robust platform for benchmarking method performance. Our analyses indicate that neglecting within-patient correlation jeopardizes type I error control. We show that, in line with some previous reports and in contrast with others, Poisson Generalized Estimation Equations provide a useful and flexible framework for addressing these issues. We also show that pseudobulk approaches outperform single-cell level methods across the board. In this work, we resolve the conflicting results regarding the utility of GEEs and their performance relative to pseudobulk approaches. As such, we provide valuable guidelines for researchers navigating the complex landscape of gene expression modeling, and offer insights on choosing the most appropriate methods based on the specific structure and design of their datasets.

In single-cell transcriptomics, differential gene expression (DE) analyses typically focus on testing differences in the average expression of genes between cell types or conditions of interest. Single-cell transcriptomics, however, also has the promise to prioritise genes for which the expression differ in other aspects of the distribution. Here we develop a workflow for assessing differential detection (DD), which tests for differences in the average fraction of samples or cells in which a gene is detected. After benchmarking eight different DD data analysis strategies, we provide a unified workflow for jointly assessing DE and DD. Using simulations and two case studies, we show that DE and DD analysis provide complementary information, both in terms of the individual genes they report and in the functional interpretation of those genes.

RNA-sequencing (RNA-seq) is increasingly used to diagnose patients with rare diseases by prioritising genes with aberrant expression and/or splicing. State-of-the-art methods for detecting aberrant expression and splicing, however, are extremely slow. The latter, also discard much information because they only use junction reads to infer aberrant splicing. In this contribution, we show that replacing the offset for library size unlocks conventional bulk RNA-seq workflows for fast and scalable differential usage, aberrant splicing and expression analyses. Our method, saseR, is several orders of magnitude faster than the state-of-the-art methods and dramatically outperforms these in terms of sensitivity and specificity for aberrant splicing, while being on par with these inferring differential usage and aberrant expression. Finally, our framework is also very flexible and can be used for all applications that involve the analysis of proportions of short- or long RNA-seq read counts.

Alternative splicing produces multiple functional transcripts from a single gene. Dysregulation of splicing is known to be associated with disease and as a hallmark of cancer. Existing tools for differential transcript usage (DTU) analysis either lack in performance, cannot account for complex experimental designs or do not scale to massive single-cell transcriptome sequencing (scRNA-seq) datasets. We introduce satuRn, a fast and flexible quasi-binomial generalized linear modelling framework that is on par with the best performing DTU methods from the bulk RNA-seq realm, while providing good false discovery rate control, addressing complex experimental designs, and scaling to scRNA-seq applications.

Uhlen et al. (Reports, 18 august 2017) published an open-access resource with cancer-specific marker genes that are prognostic for patient survival in seventeen different types of cancer. However, their data analysis workflow is prone to the accumulation of false positives. A more reliable workflow with flexible Cox proportional hazards models employed on the same data highlights three distinct problems with such large-scale, publicly available omics datasets from observational studies today; (i) re-analysis results can not necessarily be taken forward by others, highlighting a need to cross-check important analyses with high impact outcomes; (ii) current methods are not necessarily optimal for the re-analysis of such data, indicating an urgent need to develop more suitable methods; and (iii) the limited availability of potential confounders in public metadata renders it very difficult (if not impossible) to adequately prioritize clinically relevant genes, which should prompt an in-depth discussion on how such information could be made more readily available while respecting privacy and ethics concerns.